The liver X receptor [LXR] was first discovered in 1995 as a new member of the nuclear receptor superfamily 1) and was subsequently found to be activated by oxygenated cholesterol derivatives 2) . Initially, this receptor was identified in tissue obtained from a rat liver 3) , with no known endogenous ligands, and was named LXR. Later, LXR was termed an 'adopted' nuclear receptor with the discovery of oxysterols 2) as endogenous ligands for this receptor.
LXR
The liver X receptor [LXR] was first discovered in 1995 as a new member of the nuclear receptor superfamily 1) and was subsequently found to be activated by oxygenated cholesterol derivatives 2) . Initially, this receptor was identified in tissue obtained from a rat liver 3) , with no known endogenous ligands, and was named LXR. Later, LXR was termed an 'adopted' nuclear receptor with the discovery of oxysterols 2) as endogenous ligands for this receptor.
LXR, being a member of the nuclear receptor superfamily, shares the ability to promote or inhibit the transcription of target genes by binding to specific sites in the promoter regions of these genes, called response elements. LXR acts as a ligand-activated transcription factor, and the initiation or blockade of target gene transcription is determined by the presence of coactivator or corepressor complexes 4) . LXR forms heterodimers with another nuclear receptor, retinoid X receptor [RXR] . The formed heterodimer then binds with specific DNA sequences known as LXRresponsive elements [LXREs] , which regulate the transcription of target genes 1) . LXR interacts with several coregulators, including PGC-1b, RIP140, GPS2 and ACS-2, which have been linked to specific metabolic processes [5] [6] [7] [8] .
The LXR/RXR heterodimer inhibits the transcription machinery of a number of target genes involved in various metabolic processes and have lipolytic/lipogenic effects on lipid metabolism. Clinical case reports have documented high cholesterol levels in hypothyroid patients and low cholesterol levels in hyperthyroid patients 21, 22) . The T4 thyroid hormone is eventually converted to T3, the active moiety of which then binds as a ligand to thyroid hormone receptors (TRs). While two isoforms of TRs, TR-α and TR-β (Nr1a1 and Nr1a2), with different subtypes (α-1, α -2, β-1, β-2 and β-3) 23) are found in the liver, TR-β has been found to play a major role in gene regulation and is involved in crosstalk with LXR as shown in Fig. 2 24, 25) . TRs and LXRs are both nuclear receptors, with different receptor subgroups showing similarity in molecular mechanisms, target genes and physiological roles 26) . Similar to LXR, TR forms a heterodimer with RXR upon activation. The TR-RXR heterodimer then binds with DNA-responsive elements, TREs, as LXR-RXR binds to LXREs. TREs and LXREs exhibit structural similarity, with direct repeat of the basic nucleotide sequence AGGTCA spaced by four nucleotides (DR-4) 1, 26) . Cholesterol catabolism by CYP7A1 in the liver produces bile acids. TRs and LXRs both regulate cholesterol catabolism into bile acids by CYP7A1, a rate limiting enzyme, in rodents 27) . It was demonstrated in one study that hypothyroid mice have undetectable levels of CYP7A1 mRNA, while treatment with T3 thyroid hormone increased the level of CYP7A1 28) . LXR activation also regulates CYP7A1 transcription via LXREs. Impaired CYP7A1 levels have been reported in LXRα −/− mice, resulting in hepatic cholesterol accumulation 29) . Furthermore, activation of the CYP7A1 gene expression is induced by crosstalk between TR-β and LXR-α, thereby controlling cholesterol metabolism 30) . The LXR-dependent regulation of CYP7A1 is limited to rodents and has no effect in humans 31) .
LXR and PPAR: Crosstalk
There is a potential interaction or crosstalk between LXR and PPAR. Both of these nuclear receptors form heterodimers with RXR (retinoid X receptor), which enhances binding to their respective DNA response elements 1, 32) . The LXR ligand activates hepatic LXRα, stimulating crosstalk with PPARα/ RXR and thus leading to suppression of the expression of PPARα target genes involved in lipid degradation, while PPARα activation inhibits LXR ligand-induced signaling in hepatocytes involved in lipid synthesis.
The expression of LXRα is subject to a number . Interestingly, it has been demonstrated that glucose and glucose-6-phosphate are able to bind and activate LXR in vitro 18) . The identification of cholesterol metabolites as endogenous ligands already hints toward the physiological processes regulated by LXRs. Upon their activation, LXRs induce the transcription of multiple genes involved in cholesterol efflux, conversion and transport 19) . However, LXRs also modulate the expression of genes involved in glucose and fatty acid metabolism while transrepressing those involved in inflammatory processes 20) .
LXR and Thyroid Hormone Crosstalk
Thyroid hormones, such as T4 and T3, are PPAR α heterodimers, leading to the reduction of PPAR α/RXR α formation. In support of these findings, the in vivo administration of the LXR ligand in mouse and rat primary hepatocytes substantially decreases the hepatic mRNA levels of PPAR α-targeted genes under both basal and PPAR α agonistinduced conditions. In one study, the amount of nuclear PPAR α /RXR heterodimers in the mouse livers was increased by treatment with a PPAR α ligand and suppressed by treatment with a superimposed LXR ligand 38) .
LXR and Dietary Cholesterol Absorption
LXR activation results in a reduction in intestinal cholesterol absorption as depicted in Fig. 1 . However, it was later demonstrated that ABCA1 is present on the basolateral membrane of enterocytes and, ergo, does not mediate dietary cholesterol absorption, although it is involved in the generation of HDL via cholesterol efflux 39) . ABCG5 and ABCG8 play key roles in preventing the intestinal absorption of excess dietary cholesterol from the gut and enhancing cholesterol efflux from hepatocytes into bile as ABC transporters 40) . The ABCG5 and ABCG8 mRNA levels, present in both hepatocytes and enterocytes, are increased by the activation of LXR. No changes are observed in the ABCG5 or ABCG8 gene expression in mice lacking of regulatory mechanisms. These mechanisms were first examined in a study that determined the potential for crosstalk between peroxisome proliferator-activated receptors [PPARs] and LXRs 33) . In rat hepatocytes, both in vivo and in vitro, unsaturated fatty acids have been found to strongly increase the mRNA and protein expression levels of LXRα, while causing no changes in the expression of LXRβ. This upregulated expression of LXRα is primarily due to an increase in the transcriptional rate and binding of the nuclear receptor PPARα to a PPAR response element [PPRE] in the 5' flanking region of the murine LXRα gene 33) . Subsequently, a PPRE was identified in the human LXRα 5'-flanking region 34) . In conjunction with the observation that unsaturated fatty acids are competitive inhibitors of LXR ligands 35) , these studies indicate the complex role of unsaturated fatty acids in LXR regulation, as these compounds can act via PPARα to induce the LXRα expression and may also act directly to decrease the LXR transcriptional activity.
Peroxisome proliferator activated receptor [PPAR]α regulates energy depletion via fatty acid degradation 36) ,while sterol regulatory element-binding protein-1c, which is activated by liver X receptor [LXR] , is involved in fatty acid synthesis 37) . Gel shift assays have demonstrated that LXR reduces the binding of PPAR α/retinoid X receptor [RXR] α to peroxisome proliferator response elements. The addition of increasing amounts of RXR α has been found to restore these inhibitory effects in both luciferase and gel shift assays, thus suggesting the presence of RXR α competition. Meanwhile, in vitro protein binding assays have demonstrated that activation of LXR by an LXR agonist promotes the formation of LXR/RXR α and, more importantly, LXR/ . Effluxed cholesterol is then esterified by lecithin and cholesterol acyltransferase and is subsequently moved to the core of the HDL lipoprotein particle, where it transforms nascent discoidal HDL particles into spherical mature HDL particles that are ultimately taken up by the liver.
LXRs control RCT via several potential mechanisms.
For example, LXRs stimulate intracellular cholesterol mobilization to the plasma membrane, thus enhancing the availability of cholesterol for efflux to extracellular acceptors. Several apolipoproteins and lipid-modulating enzymes involved in cholesterol efflux and HDL remodeling are transcriptional targets for LXRs.
Indeed, LXRs stimulate the expression of apoE in murine macrophages and adipose tissue, but not the liver 47) . Previous studies have also demonstrated that LXR activation in cultured HepG2 cells and/or in vivo in mice results in an increased expression and plasma activity of the enzyme phospholipid transfer protein [PLTP] , which catalyzes the exchange of phospholipids between HDL particles and triglyceride-rich lipoproteins, resulting in an increased level and size of LXRα and LXRβ, indicating that ABCG5 and ABCG8 are direct targets of LXRα and LXRβ 41) . Niemann-Pick C 1 like 1 [NPC1L1] is a protein present in the brush border membrane of enterocytes in the small intestine and has been identified to be an enteric transporter of dietary cholesterol 42) . NPC1L1 is a major contributor to the regulation of intestinal cholesterol absorptio 43) . Many studies have ostensibly proven that synthetic LXR activators enhance free cholesterol transport to the plasma membrane and inhibit intestinal cholesterol absorption by reducing the expression of NPC1L1.
One study showed that intestinal cholesterol absorption is required for LXR agonists to increase the plasma HDL-C level by treating mice lacking NPC1L1 [L1-KO mice] with the LXR agonist TO-901317 for seven days. In that study, treatment with TO-901317 failed to raise the plasma HDL-C level, while inducing greater fecal cholesterol excretion in L1-KO mice compared with that observed in control mice 44) . A recent study also demonstrated that LXR agonists decrease the NPC1L1 gene expression in human Caco-2/TC-7 enterocytes 45) . These results indicate that NPC1L1 is essential for LXR agonists to increase the plasma HDL-C level and that LXRs decrease intestinal cholesterol absorption via downregulation of the intestinal NPC1L1 expression.
LXR and RCT
RCT, reverse cholesterol transport, includes a molecules from the inner to outer leaflet of the canalicular membrane. Finally, the functional complex ABCG5/G8 pumps cholesterol into the bile. Cholesterol is only slightly soluble in aqueous solutions; however, it is made soluble in bile by bile salts and phospholipids.
During a meal, bile acids are released into the duodenum. The vast majority of bile acids are subsequently reabsorbed throughout the intestine and return via the portal blood to the liver, where they exert a negative retro feedback loop on bile acid synthesis in which recirculated bile acids are again secreted into the bile after a meal. Only a fraction of bile acids escape intestinal absorption and are secreted in feces. This constitutes the main physiological pathway of cholesterol elimination from the body. The enterohepatic circulation and feedback regulatory loop of bile acid synthesis and excretion constitute the essential mechanisms underlying the maintenance of cholesterol and bile acid homeostasis, thus preventing bile acid accumulation and avoiding toxicity as well as cholestasis. The different steps involved in bile acid metabolism are tightly controlled by the complementary and coordinated actions of LXR and the Farnesoid X receptor [FXR] , which acts as a bile acid sensor 56) . In rodents, LXRα stimulates the expression of CYP7A1 by binding to an LXRE present in the CYP7A1 promoter. Therefore, rats and mice have the capacity to convert dietary cholesterol into bile acids 57) . In contrast to that observed in rats and mice, LXRα agonist treatment suppresses the expression of CYP7A1 in primary human hepatocytes 58) , which may be due to the direct induction of a small heterodimer partner, a gene that with a repressive effect on CYP7A1 via liver receptor homolog 1 [LRH1; also called FIF in rats and CPF in humans] 59) . The excretion of free cholesterol into the bile is another major route of elimination of excess cholesterol from the liver. In the liver, ABCG5 and ABCG8 have been proposed to transport cholesterol from hepatocytes to the bile canaliculi. ABCG5 and ABCG8 are half transporters that form obligate heterodimers and are both regulated by LXR activation 60) . ABCG5 and ABCG8 are also expressed in the apical membrane of enterocytes and at the canalicular membrane of hepatocytes. These transport proteins promote the secretion of hepatic cholesterol into the bile. Mice that lack ABCG5 and/or ABCG8 demonstrate a significant decrease in the biliary cholesterol level and cholesterol accumulation in the liver after cholesterol feeding 40) .
HDL-c 48) . Furthermore, LXRs activate the human cholesterol ester transfer protein [CETP] gene expression 49) , which facilitates the transfer of cholesterol ester and triglycerides between HDL and apoB-containing lipoprotein particles. As LXR is not expressed in rodents, but rather in humans, a previous study showed that LXR agonist treatment does not increase the HDL-cholesterol levels in human CETP transgenic mice 50) . The expression of lipoprotein lipase [LPL] , an enzyme catalyzing the hydrolysis of lipoprotein triglycerides that is also involved in the maturation of HDL, is regulated by LXR 51) . LXRs enhance RCT via direct actions in macrophages. In contrast, ABCA1 does not directly interact with mature HDL particles, although two other members of the ABC superfamily, ABCG1 and ABCG4, have been demonstrated to be mediators of cholesterol efflux from cells to HDL, which stimulates the atheroprotective activity of HDL 52) . ABCG1 is highly expressed in macrophages [more so than ABCG4], and its activity likely underlies the relationship between the HDL level and the risk of atherosclerosis. Moreover, in mice fed a low-fat diet, LXRα-and LXRβ-deficiency results in the significant accumulation of cholesterol in macrophages of the spleen, lungs and arterial walls, with a concomitant decrease in the hepatic ABCA1 gene expression 53) . In addition, recent data demonstrate that pharmacological activation of LXRs in vivo promotes RCT from cholesterol injected-loaded macrophages, accompanied by the upregulation of ABCA1, ABCG1, ABCG5 and ABCG8 in both the liver and intestines 54) .
LXR and Bile Acids
Bile fluid contains water, cholesterol, phospholipids [primarily phosphatidylcholine], bile salts, bilirubin and bicarbonate ions. Bile acid synthesis and secretion constitute the major route of elimination of cholesterol from the body. Bile acids are produced in the liver from cholesterol. Furthermore, the classical pathway of bile acid synthesis is initiated by the 7α -hydroxylation of cholesterol catalysed by cytochrome P450 cholesterol 7α-hydroxylase [CYP7A1], which encodes the rate-limiting enzyme of this pathway 55) . Bile acids are then conjugated to glycine or taurine prior to secretion into the bile. The biliary secretion of lipid and bile salts is controlled by hepatic cholesterol, phospholipids and bile salt transporters located on the hepatocyte canalicular membrane. The human multidrug-resistant 3p-glycoprotein, also known as ABCB4 [corresponding to the murine Mdr2 p-glycoprotein], translocates phosphatidylcholine been shown to increase the GLUT4 expression in adipose tissue, but not skeletal muscle 69, 71, 74) , as well as raise the insulin-mediated glucose uptake and oxidation levels in human differentiated myotubes 75) .
LXR and Alzheimer's Disease
Cholesterol accumulation has been demonstrated to be one of the prime culprits of the pathology of Alzheimer's disease. An increased brain cholesterol content and/or irregular distribution increases the β and γ secretase activities 76, 77) , which cleaves amyloid precursor protein 78) , thus leading to Aβ production 79) , whereas a decreased intracellular cholesterol concentration promotes the non-amyloidogenic activity of α secretase 80) . Both in vivo and in vitro studies have highlighted the role of LXR activation in reducing Aβ production. Moreover, Lxr α −/− and Lxr β −/− have been found to enhance Aβ plaque production and thus further deteriorate the pathology of Alzheimer's disease in an animal model 81) . ABCA-1, a transporter in the brain, pumps cholesterol out of cells, resulting in lipid efflux and helping to achieve the proper redistribution of lipids in the brain. Increased transcription of the ABCA-1 gene is considered to be beneficial, as it upregulates the ABCA-1 transporter expression, thereby regulating the cholesterol levels in the brain 82) . In one preclinical study, the LXR agonist, T0901317, increased the ABCA-1 expression and decreased the Aβ production 83) . Hence, the modulation of APP processing and reduction of Aβ production induced by LXR makes it a promising target for the treatment of Alzheimer's disease.
Cholesterol is responsible for maintaining various neuronal functions in the brain. For example, cholesterol prevents β-amyloid accumulation. The final catalytic synthesis of cholesterol is carried out by 24-dehydrocholesterol reductase, an enzyme coded by the Selective Alzheimer's disease indicator-1 (Seladin-1) gene, the overexpression of which increases the de novo synthesis of cholesterol in neurons and has been found to protect neuronal cells against oxidative stress and β-amyloid accumulation, ultimately preventing neuronal apoptosis. Recent studies have demonstrated crosstalk between TR and LXR in the regulation of the Seladin-1 expression. Both TR and LXR upregulate the Seladin-1 expression. However, in mice, it has been demonstrated that LXR-α upregulates the Seladin-1 expression only under hypothyroid conditions or in the presence of mutant TR-β, otherwise the Seladin-1 expression is predominately regulated by TR-β. In contrast, in humans, both TR-β and LXR-α competitively bind to specific sites on the
LXR and Fatty Acids
LXR activation increases the expression of genes of fatty acid biosynthesis [i.e. lipogenesis], whereby it induces fatty liver and raises the plasma triglyceride level [hypertriglyceridemia] by promoting the secretion of large TAG-rich VLDL particles in mice 61) . It has been reported that the induction of the fatty acid transporter CD36 in response to pharmacological LXR activation contributes to hepatic lipid accumulation, presumably by increasing the hepatic fatty acid uptake 62) . Severe hepatic steatosis develops in mice upon LXR agonist treatment; many studies have explained this effect based on the direct upregulation of SREBP1c, the major SREBP1 isoform, in the liver, which stimulates the transcription of lipogenic genes, such as fatty acid synthase [FAS], acetyl-coA carboxylase [ACC] and stearoyl-coenzyme A desaturase 1 [SCD1], a rate-limiting enzyme necessary for the biosynthesis of monounsaturated acids 63, 64) . In one study, it was found that angiopoietin-like protein 3 [Angptl3] 65) , a liver-secreted protein that increases the plasma triglyceride level by inhibiting the LPL activity in different tissues and the free fatty acid levels by activating lipolysis in adipocytes, exhibits an increased expression, while apoA-V is downregulated, following LXR activation 66) .
Diabetes and LXR
The apparent role of LXR in glucose homeostasis has been documented in various studies demonstrating potent glucose-lowering and insulin-sensitizing effects of synthetic LXR activators. In one study, the administration of T0901317, an LXR activator, normalized the plasma glucose levels in db/db mice and Zucker diabetic fatty [ZDF] rats 67) , while leaving glycemia unaffected in non-diabetic animal models 68) . GW3965 and T0901317 also improve insulin sensitivity in db/db mice and Zucker fatty rats, as well as high-fat diet-fed rodents [67] [68] [69] [70] [71] . Several potential mechanisms for the antidiabetic actions of LXR agonists have been proposed. For example, LXR activation reduces the mRNA level of peroxisome proliferatoractivated receptor γ coactivator-1α (PGC-1α) in the rodent liver 68, 71) , the main controller of hepatic glucose biogenesis 72) . In addition, a high expression of SREBP-1c induced by LXR activation downregulates the expression of phosphoenolpyruvate carboxykinase 73) . These two explanatory mechanisms of LXR activation can account for the induced inhibition of hepatic glucogenesis. Furthermore, LXR agonists have proteinases [MMPs] and cytokines in keratinocytes, which consequently damages the extracellular matrix. Repeated exposure results in wrinkle formation due to incompletely degraded collagen accumulation in the dermis. In the skin, LXRs are expressed in keratinocytes [LXRα and -β in human keratinocytes and LXRβ in murine keratinocytes], and their natural ligands have been shown to induce keratinocyte differentiation and improve the epidermal barrier function. Topical treatment with an LXR ligand, T1317, significantly reduces UV-induced abnormal skin thickening in vivo in a dose-dependent manner. LXR is thus a potential target for treating skin aging and photoaging problems 93) .
LXR and Adrenal Steroids
LXRα and LXRβ are both found in all three layers of the adrenal cortex (the zona glomerulosa, fasciculata and reticularis), with a higher expression of LXRβ 94) . Human adrenal cell lines have been shown to possess LXR-responsive genes involved in adrenal hormone biosynthesis. LXR activation has different in vivo and in vitro effects on adrenal steroidogenesis. For example, the adrenal cortex contains multiple steroidogenesis enzymes, including: a) CYP11A1 (cholesterol side chain cleavage enzyme), which converts cholesterol to pregnenolone, the first step towards steroid hormone biosynthesis 95) , b) StAR (steroidogenic acute regulatory protein), which transports cholesterol from the outer to inner mitochondrial membrane, determining the availability of cholesterol for steroid hormone production, thus making it a rate-limiting enzyme 96) , and c) SF1 (steroidogenic factor 1), which is involved in the transcription of various steroidogenic enzymes, including CYP11A1 95) . In addition to these steroidogenic enzymes, other genes in the adrenal cortex are involved in lipid homeostasis, primarily HMGCR, ABCA1 and LDL-R, which play a role in cholesterol biosynthesis, efflux and uptake, respectively.
In vitro LXR activation inhibits all steroidogenic genes in the adrenal cortex, thereby suppressing steroid hormone production. Oxysterols, including 22R-hydroxycholesterol and 20S-hydroxycholesterol, are produced as intermediates during cholesterol conversion to pregnenolone by CYP11A1; these oxysterols are well-recognized to be LXR activators. It has been suggested that thus activated LXR switches off the steroidogenesis pathway in the adrenal glands by inhibiting various genes involved in steroidogenesis 97) . In contrast to that observed in the in vitro setting, LXR activation in vivo increases the corticosteSeladin-1 promoter, thus upregulating the Seladin-1 expression 84, 85) .
LXR and Inflammation
A well-recognized driving force behind the development of atherosclerotic lesions is chronic inflammation. Inflammation plays a major role in both the initiation and progression of atherosclerotic lesion formation. As an anti-inflammatory transcription factor, LXR regulates the innate and adaptive immune responses, apoptosis and phagocytosis. In addition, LXR agonists demonstrate anti-inflammatory effects in various animal models of inflammation, and LXRs antagonize the cytokine-mediated expression of proinflammatory genes in macrophages via the transcriptional silencing of proinflammatory transcription factor nuclear factor (NF)-κB 86) . It has also been proven that LXR activation inhibits the gene transcription of various inflammatory genes, including TNF-α, COX-2, IL-1β, MMP-9 and iNOS [87] [88] [89] . Such effects are not observed in LXR α/β knockout animals 90) . In one experimental autoimmune encephalitis (EAE) mouse model, an LXR agonist suppressed the expression of IFN-γ, intercellular adhesion molecule-1(ICAM-1), TNF-α and MMP-9 and reduced the expression of class Ⅱ MHC antigens, thereby suppressing immunity 91) . Meanwhile, in a rat liver inflammatory model, LXR agonist treatment achieved a reduction in increased bilirubin and alanine aminotransferase plasma levels, decreased mast cell infiltration and suppressed the inflammatory gene expression, thus ameliorating an inflammatory liver condition 92) .
LXR and the Skin
Chronological aging and photoaging are the two biological processes of skin aging. Chronological aging, in which physiological changes occur in the skin over time, results in dry, thin, wrinkled and easily injured skin. This process is characterized by cellular senescence, leading to decreased keratinocyte proliferation, improper terminal differentiation, reduced neutral lipid and collagen synthesis and an increased production of prostaglandin E2 [PGE2] and MMP as well as oxidative damage. Solar UV radiation damages the skin, causing it to age prematurely, which results in the photoaging process involving epidermal keratinocytes, dermal fibroblasts and infiltrating neutrophils. UV exposure induces the activation of activator protein 1 [AP-1] and nuclear factor-κB [NF-κB] in the skin, leading to the expression of matrix metallo-in these processes result in spermatogenic impairment and thus infertility. Interestingly, proliferation and apoptosis are altered in LXRβ-and LXRα-deficient mice, respectively, although these mice do not exhibit any fertility problems. Indeed, in lxrβ −/− mice, a lower rate of proliferation is associated with a compensatory decline in apoptosis. In contrast, among lxrα −/− mice, a higher level of apoptosis is associated with a compensatory increase in proliferation. These compensatory effects may thus explain the normal fertility observed in single LXR knockout mice. Meanwhile, the lack of both LXRs leads to a dramatic decline in proliferation and increase in apoptosis. This may be one explanation for the complete loss of germ cells, resulting in infertility 102) . Retinoic acid, a metabolite of vitamin A, mediates the growth and development of vitamin A and appears to play a vital role in various testicular functions. It has been demonstrated that excess vitamin A leads to the formation of testicular lesions and spermatogenic disorders, whereas vitamin A deficiency induces the early cessation of spermatogenesis and adversely affects testosterone production 105) . Furthermore, the lack of LXR results in an increased RARα, RARβ and RALDH-2 expression, which consequently induces retinoic acid signaling, as demonstrated by the expression patterns of known RAR target genes, e.g. dmc1 and scp3, potentially causing spermatogenic disorders. Moreover, lipid accumulation is observed in the Sertoli cells of rats with hypervitaminosis A 106) , suggesting a link between retinoids and lipids.
Therefore, both LXR isoforms are involved in the regulation of testosterone production at the testicular and pituitary levels, whereas germ cell apoptosis and proliferation are individually regulated by LXRα and LXRβ, respectively. In addition, LXRs regulate lipid and retinoic acid metabolism via the transcriptional activation of enzymes and membrane transporters. The lack of LXRα and LXRβ results in severe infertility due to impairment in various pathways, of which aberration in lipid metabolism appears to have a central effect 102) .
Conclusion
Several studies conducted over the last decade have expanded our knowledge regarding the roles of LXRs. By upregulating the expression of ATP-binding cassette transporters [ABCs] , including ABCG5/G8, and downregulating the expression of NPC1L1, LXRs prevent the intestinal absorption of excess dietary cholesterol and enhance the efflux of absorbed cholesterol. In addition, LXRs stimulate the expression of rone level in the plasma in mice, which suggests that LXR has a meddling effect on the HPA (hypothalamus-pituitary-adrenal) axis. Several LXR-responsive genes are located in the pituitary gland, which increases the ACTH (adrenocorticotropic hormone) production upon LXR activation. 11β-HSD1 (11β -hydroxysteroid dehydrogenase type 1) enzyme in the pituitary converts inactive glucocorticoid hormone to active cortisol, while increased active cortisol signals the feedback inhibition of ACTH in pituitary cells. LXR activation therefore inhibits the 11β-HSD1 enzyme and thus conversion to active cortisol, removing the stop signal on ACTH production 97, 98) . Recently, the effects of LXR in increasing ACTH production were confirmed in a study that proved that LXR-α positively regulates the gene expression of proopiomelanocortin (POMC), from which ACTH is cleaved, in the pituitary gland 99) . Further demonstrating the involvement of LXR-α, the mRNA levels of LXR-α were found to be higher than those of LXR-β in ACTH-secreting pituitary adenomas compared to that noted in other pituitary adenomas and normal pituitary tissues 100) . ACTH binds to the ACTH-R (ACTH-receptor) in the adrenal cortex, where it induces steroid hormone production. Increased ACTH production in the pituitary cancels the inhibitory effects of LXR activation on adrenal hormone biosynthesis. Therefore, LXR agonists with BBB-penetrating properties have different effects than those without, as LXR activates ACTH production in the pituitary and increases adrenal steroidogenesis.
LXR and Male Fertility
The cardinal functions of the testis are testosterone production and spermatogenesis. Leydig and Sertoli cells are testicular cells. Leydig cells secrete testosterone, while Sertoli cells provide structural and nutritional support for developing germ cells 101) . Furthermore, Leydig cells express LXRα, while Sertoli cells LXRβ, whereas germ cells express both LXRs. LXRα regulates basal testosterone synthesis and is involved in the control of germ cell apoptosis. In contrast, LXRβ controls lipid metabolism in Sertoli cells by regulating cholesterol export, as well as germ cell proliferation. Moreover, both LXRs together regulate ligand-induced steroidogenesis, fatty acid metabolism and, surprisingly, the retinoic acid signaling pathway in the testis 102) . Spermatogenesis is maintained by a delicate balance between cell proliferation, differentiation and death 103, 104) . It has been hypothesized that alterations CYP7A1, thereby converting cholesterol in hepatocytes into bile acids and promoting their excretion into the bile. This effect is only observed in nonhuman models. Furthermore, LXR activation stimulates HDL particle synthesis by increasing reverse cholesterol transport. As inflammation and dyslipidemia are the major culprits of atherogenesis, targeting LXRs appears to be therapeutically promising. These nuclear receptors are not simply limited to lipid homeostasis, but rather extend their roles to various other physiological functions. Via complex mechanisms, they regulate adrenal steroid production and ameliorate Alzheimer's disease. Moreover, LXRs are expressed in skin keratinocytes, where they reduce UV-induced abnormal skin thickening and improve the epithelial barrier function. LXRs also play an important role in the reproductive function, as a lack of LXRs results in male infertility, and these receptors also exhibit various anti-inflammatory actions. However, the beneficial effects of LXRs are associated with stimulation of lipogenesis. Future studies should concentrate on dissociating the good effects from the bad effects of LXRs. Overall, LXRs are very promising and useful targets for several diseases, including atherosclerosis and other lipid disorders, as well as diabetes, skin aging, Alzheimer's disease and male fertility.
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